Introduction {#s1}
============

The brain is a complicated organ which not only requires specific connections between neurons to form circuits, but also many neuronal types with variations in morphology, neurotransmitters and receptors. While mechanisms controlling neuronal diversity have not been globally examined, studying neural stem cells in the mouse and fruit fly have given insight into key aspects of neuronal specification. For example, in the mouse neocortex, radial glial progenitors (RGP) are multipotent---they produce a variety of neuron types organized sequentially into six layers, and then produce glia ([@bib1]). In vivo lineage analysis demonstrated that after a stage of symmetric cell division, an individual neurogenic RGP produces an average of 8--9 progeny (range of 3--16) that can span all cortical layers ([@bib15]). In *Drosophila*, clonal analysis has demonstrated a vast range of stem cell-specific lineage programs ([@bib26]; [@bib72]). On one extreme, lineage tracing of a single antennal lobe (AL) stem cell revealed a remarkable series of 40 morphologically distinct neuronal types generated sequentially ([@bib34]; [@bib71]). In light of these observations, a fundamental goal is to understand how distinct neuronal types correctly differentiate from a single progenitor. Despite a fundamental role for temporal patterning to create diverse neuronal lineages, our understanding of neuronal temporal patterning is still limited. While scientists have discovered key temporal factors expressed in neural progenitors, much less is understood about how these signals are interpreted, that is what factors lie downstream of the specification signals to determine distinct neuronal temporal fates.

Despite its relatively small brain, *Drosophila* is leading the charge on studies of neuronal temporal fate specification ([@bib11]; [@bib12]; [@bib42]). Many temporal transcription factors originally discovered in the fly have since been confirmed to have conserved roles in mouse retinal and cortical development ([@bib21]). Moreover, temporal expression of an RNA binding protein, IGF-II mRNA-binding protein (Imp), that guides temporal patterning in the postembryonic fly brain ([@bib36]) is also implicated in mouse brain development ([@bib47]). *Drosophila* brain development is an excellent model for studying neurogenesis; the neural stem cells, called neuroblasts (NB), are fixed in number, their modes of division are well characterized, and each NB produces a distinctive series of neurons which change fate based on birth order ([@bib72]). Finally, the fruit fly is a genetically tractable system making it ideal for studying gene networks involved in cell fate decisions.

In *Drosophila*, cycling NBs express age-dependent genes that provide the serially derived newborn neurons with different temporal factors. In the embryonic ventral nerve cord and the optic lobe, the NBs express a rapidly changing series of four to six temporal transcription factors (tTF), some of which are directly inherited by the daughter neurons ([@bib6]; [@bib24]; [@bib27]; [@bib33]). Each tTF directly acts to specify a small number (two to four) of neuronal progeny. The neuronal progeny produced from one tTF window to the next can be quite different. The tTF series are intrinsically controlled, which ensures reliable production of all neuron types, but lacks the ability to adapt to complicated or changing conditions.

A separate mechanism is therefore required for adult brain development---both to produce very long series of related neuronal types and to coordinate with organism development. This can be accomplished utilizing protein gradients and hierarchical gene regulation, such as the mechanism used to pattern the fly's anterior/posterior (A/P) axis ([@bib53]; [@bib54]; [@bib61]; [@bib66]). In *Drosophila* A/P patterning, the embryo is progressively partitioned into smaller and smaller domains through layered gene regulation. This is initiated by asymmetric localization maternal mRNAs, *bicoid* (anterior) and *nanos* (posterior). The resulting opposing proteins gradients then act on maternal mRNA translation, and in the case of Bicoid, zygotic transcription. The embryo then progresses through expression of maternal morphogen gradients, then zygotic expression of gap genes to determine broad embryo regions, followed by progressive segmentation by the pair-rule and segment polarity genes, and finally specification by the homeotic selector genes.

Notably, in postembryonic brain development, we have discovered two proteins in opposing temporal gradients expressed in NBs. These proteins are Imp and Syncrip (Syp) RNA-binding proteins. Imp and Syp control neuronal temporal fate specification as well as the timing of NB termination (decommissioning; [@bib36]; [@bib52]; [@bib63]; [@bib70]). Imp promotes and Syp inhibits translation of the BTB-zinc finger nuclear protein, *chinmo* (chronologically inappropriate morphogenesis), so that protein levels in newborn neurons descend over time ([Figure 1A](#fig1){ref-type="fig"}) ([@bib36]). The level of Chinmo correlates with the specification of multiple neuronal temporal fates ([@bib73]). Discovering downstream layers in the Imp/Syp/Chinmo hierarchy is essential to fully comprehend the intricacies of temporal patterning in brain development.

![Mamo expression coincides with the generation of α'/β' neurons in the Mushroom Body (MB) neuronal lineages.\
(**A**) Temporal gradients specify postembryonic neurons of the MB lineages into three sequential neuronal classes ([@bib31]; [@bib36]). Newborn neurons are colored to illustrate expression levels of Imp (red), Syp (blue), and Chinmo (gray stars). ALH = after larval hatching, APF = after pupal formation. (**B--D**) MB lineages (*OK107 \> GFP*) immunostained for GFP, Chinmo (Rat-anti-Chinmo), and Mamo at different developmental times. A single focal plane near the MB NB is shown. Newborn neurons (NN) are identified by the very dim GFP expression near the NB as described by [@bib73] and outlined in white. Young/maturing neurons are immediately adjacent to the NNs with a slightly higher GFP intensity and outlined in yellow. Chinmo levels in NNs decline over time. Mamo staining is visible at 84 hr ALH in young/maturing neurons (**C**). At 24 hr APF, Mamo expression is strong in older neurons (gray dashed outline), but absent from young/maturing neurons (**D**). Scale bar = 20 μm. Images are representative of n \> 18. The quantification of Chinmo and Mamo staining is in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.\
10.7554/eLife.48056.004Figure 1---source data 1.Intensity of Chinmo and Mamo staining at different developmental times.](elife-48056-fig1){#fig1}

Temporal regulation in the fly brain is easily studied in the relatively simple mushroom body (MB) neuronal lineages which are comprised of only three major cell types. These neuronal types are born in sequential order: beginning with γ neurons, followed by α'/β' neurons, and finally α/β neurons ([@bib25]; [@bib31]). Imp and Syp are expressed in relatively shallow, opposing temporal gradients in the MB NBs. Modulation of Imp or Syp expression results in shifts in the neuronal temporal fate. Imp and Syp post-transcriptionally control Chinmo so that it is expressed in a gradient in the first two temporal windows ([@bib36]). γ neurons are produced in a high Chinmo window, α'/β' neurons are produced in a low Chinmo window, and α/β neurons are produced in a window absent of Chinmo expression ([@bib73]). Moreover, altering Chinmo levels can shift the temporal fate of MB neurons accordingly, strongly implicating dose-dependent actions, similar to that of a morphogen. Despite its importance in temporal patterning, the mechanisms underlying the dosage-dependent effects of Chinmo on neuronal temporal identity is unknown.

Here we describe Mamo (maternal gene required for meiosis, [@bib46]), a BTB zinc finger transcription factor critical for temporal specification of α'/β' neurons. Mamo is expressed in a low Chinmo temporal window and Mamo expression can be inhibited both by high Chinmo levels and loss of *chinmo.* Additionally, Mamo is post-transcriptionally regulated by the Syp RNA binding protein. This layered regulation, which is utilized in both MB and AL lineages results in a discrete window of Mamo expression in young, post-mitotic neurons. In the MB lineages, this window corresponds to the middle window of neurogenesis and we establish that Mamo codes for middle temporal fate(s); α'/β' neuronal characteristics are lost when Mamo levels are reduced and ectopic Mamo drives an increase in α'/β' neuron production. The temporal fate determination paradigm we describe utilizes multiple levels of gene regulation. Temporal fate specification begins in the stem cell and proceeds in a hierarchical manner in successive stages where top and second-tier factors work together to specify neuronal temporal fate. Our data suggest that Mamo deciphers the upstream temporal specification code and acts as a terminal selector to determine neuronal fate.

Results {#s2}
=======

Mamo expression coincides with generation of α'/β' neurons in the MB lineages {#s2-1}
-----------------------------------------------------------------------------

In order to understand how the descending Chinmo protein gradient could result in distinct temporal windows, we set out in search of potential Chinmo target genes. We identified Mamo as a candidate based on its expression pattern in the developing MB lineages. Mamo expression seems to trail weak Chinmo expression in both time and space ([Figure 1B--D](#fig1){ref-type="fig"}). α'/β' neurons are specified in a temporal window when Chinmo levels in newborn neurons are weak, beginning around 72 hr after larval hatching (h ALH) ([@bib73]) ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Mamo's expression is initiated a few hours afterwards (around 84 hr ALH) in a group of neurons that border the newborn neurons ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). This group of neurons is discernible by intermediate GFP levels driven by OK107-Gal4, and is hereafter referred to as young/maturing neurons. These data suggest that as the weak Chinmo expressing newborn neurons mature and move further from the NB, they begin to express Mamo. Conversely, Mamo is undetectable in young/maturing neurons that are destined to become γ ([Figure 1B](#fig1){ref-type="fig"}) or α/β neurons ([Figure 1D](#fig1){ref-type="fig"}). To validate that at 84 hr ALH, Mamo is in fact expressed in prospective α'/β' rather than γ neurons, we used a γ neuron-specific driver and confirmed that there is no overlap with Mamo expression ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). These results indicate a temporal induction of Mamo specifically in the prospective α'/β' neurons, consistent with Mamo being a target of weak Chinmo within the young neuron stage of neuronal maturation. γ neurons, which express high Chinmo in early larval stages, begin to express Mamo during puparium formation ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}).

Weak Chinmo initiates Mamo protein expression {#s2-2}
---------------------------------------------

To test if Mamo lies downstream of weak Chinmo, we examined the effect of altering Chinmo levels on Mamo expression. Consistent with our hypothesis, both overexpressing and eliminating Chinmo effectively abolished Mamo expression ([Figure 2B and C](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Chinmo's effect on Mamo expression appears to be cell autonomous, as wild type neurons adjacent to *chinmo* null MARCM clones continue to express Mamo ([Figure 2C](#fig2){ref-type="fig"}, yellow arrow). Conversely, targeted *chinmo* RNAi prematurely reduced, rather than eliminating Chinmo ([Figure 3---figure supplement 1B&G](#fig3s1){ref-type="fig"}). This premature reduction in Chinmo initiated early Mamo expression ([Figure 2F](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}) and thus greatly expanded (approximately 3-fold) the number of cells expressing Mamo at 84 hr ALH ([Figure 2D and G](#fig2){ref-type="fig"}). These results indicate that weak Chinmo expression is both necessary and sufficient to activate Mamo in young/maturing MB neurons.

![Weak Chinmo initiates Mamo protein expression.\
MB lineages (*OK107 \> GFP*) with different genetic manipulations immunostained for GFP and Mamo. A single focal plane near the MB NB is shown. Newborn neurons (NN) are outlined in white. Young/maturing neurons are outlined in yellow. Images are representative of n \> 18. Scale bar = 20 μm. The diagram below shows approximate levels of Imp (red), Syp (blue), and Chinmo (stars) expressed in the young/maturing neurons when they were NNs \~ 12 hr prior (as reported by [@bib36]), or [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). (**A-F**) At 84 hr ALH, Mamo staining is visible only in the young/maturing neurons in control brains (**A**) and brains expressing *chinmo-RNAi* (*D*). (**C**) *chinmo^-/-^; OK107 \> GFP* is a c*hinmo* null MARCM clone induced at newly hatched larvae (NHL). Note that *OK107* drives GFP only within the clone. MB neurons outside of the *chinmo^-/-^* clone (eyeless^+^, data not shown) express Mamo (yellow arrow). (**F**) At 60 hr ALH, Mamo staining is only visible after OK107 \> *chinmo RNAi.* (**G**) Mean number (± SEM) of Mamo positive neurons per brain hemisphere in control (gray) and *chinmo-RNAi* (black) expressing MBs (\*\*\*p\<0.005, n = 4--5). The quantification of Mamo staining is in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.\
10.7554/eLife.48056.007Figure 2---source data 1.Quantification of Mamo positive neurons.\
10.7554/eLife.48056.008Figure 2---source data 2.Mamo staining intensity in young/maturing neurons with chinmo manipulations.](elife-48056-fig2){#fig2}

Mamo requires post-transcriptional regulation by Syp {#s2-3}
----------------------------------------------------

*chinmo-RNAi* effectively reduced Chinmo levels early in development, so that immunostaining at 48 hr ALH reveals very low levels, both in newborn neurons and in older, early-born neurons ([Figure 3---figure supplement 1B and G](#fig3s1){ref-type="fig"}). Nevertheless, the initiation of Mamo expression is only shifted as early as 60 hr ALH ([Figure 2F](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}, [Figure 3---figure supplement 2A and B](#fig3s2){ref-type="fig"}). This timing correlates with the onset of Syp expression ([@bib36]), making us wonder whether Mamo could also be regulated by upstream temporal factor Syp. This would be analogous to how the pair-rule gene expression in a particular stripe is controlled by both maternal gradients and subsequent gap gene expression ([@bib60]). We therefore monitored Chinmo and Mamo expression following manipulations of Syp ([Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplements 1](#fig3s1){ref-type="fig"} and [2C](#fig3s2){ref-type="fig"}). Repressing Syp increased Chinmo expression ([Figure 3---figure supplement 1E and G](#fig3s1){ref-type="fig"}) and thus abolished Mamo expression at 84 hr ALH ([Figure 3B](#fig3){ref-type="fig"}). Ectopic Syp marginally reduced Chinmo levels ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}) and there was a concomitant shift in Mamo expression---like *chinmo-RNAi,* there was an increased number of Mamo-positive cells at 84 hr ALH ([Figure 3C](#fig3){ref-type="fig"}). It was not clear whether this result was due solely to reduced Chinmo levels or a potential role for Syp in Mamo expression. Hence, we needed to create a scenario where Syp levels and Chinmo levels were uncoupled. We first used *Syp-RNAi* to remove Syp, which positively regulates Chinmo ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}) and then added *chinmo-RNAi* to lower the Chinmo levels ([Figure 3---figure supplement 1C and G](#fig3s1){ref-type="fig"}). Intriguingly in this scenario, Mamo was still absent ([Figure 3D](#fig3){ref-type="fig"}). Without Syp, weak Chinmo was no longer sufficient to promote Mamo expression.

![Mamo protein expression requires Syp RNA binding protein.\
MB lineages (*OK107 \> GFP*) immunostained for GFP and Mamo. A single focal plane near the MB NB is shown. Newborn neurons (NN) are outlined in white and young/maturing neurons are outlined in yellow. Arrows indicate regions with Mamo protein expression. Images are representative of n \> 18. Scale bar = 20 μm. The diagram below shows the relative protein levels of Imp (red), Syp (blue), and Chinmo (stars) expressed in the young/maturing neurons when they were newborn 12 hr prior (based on [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [@bib36]). (**A-D**) Mamo expression in young/maturing neurons occurs in genotypes with low Chinmo levels (**A and C**) with the exception of *Syp-RNAi* plus *chinmo-RNAi* (**D**). Note that green dashed circle is labeling other MB neurons. Chinmo immunostaining and quantifications from earlier stages can be found in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}. Mamo levels are shown in [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}.\
10.7554/eLife.48056.012Figure 3---source data 1.Mamo staining intensity in young/maturing neurons with Syp manipulations.\
10.7554/eLife.48056.013Figure 3---source data 2.Chinmo staining intensity in newborn neurons with different genetic manipulations.](elife-48056-fig3){#fig3}

Syp has been shown to regulate mRNA stability and translation ([@bib39]). It is therefore possible that *mamo* is transcriptionally controlled by weak Chinmo but post-transcriptionally regulated by the Syp RNA-binding protein. To differentiate transcription and post-transcriptional mRNA regulation, we turned to single molecule fluorescent in-situ hybridization (smFISH). We monitored the expression of both nascent and mature *mamo* transcripts with differentially labeled intron and exon probes ([@bib37]) ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}). Bright nuclear foci of nascent transcripts indicate a site of active transcription ([Figure 4B](#fig4){ref-type="fig"}). We detected an onset of *mamo* transcription in the nuclei of newborn MB neurons starting at 72 hr ALH ([Figure 4D](#fig4){ref-type="fig"}). Mature *mamo* transcripts then gradually accumulated in the cytoplasm of young/maturing neurons ([Figure 4E](#fig4){ref-type="fig"}). Consistent with our previous results, knocking down Chinmo by targeted RNAi elicited a precocious activation of *mamo* transcription as early as 48 hr ALH ([Figure 4F](#fig4){ref-type="fig"}). When examining MBs lacking Syp that also had very weak Chinmo expression (*Syp-RNAi + chinmo-RNAi,* [Figure 3---figure supplement 1E and I](#fig3s1){ref-type="fig"}), we found sites of active *mamo* transcription at 48 hr ALH ([Figure 4I](#fig4){ref-type="fig"}). This clearly illustrates that repressing *Syp* did not delay the precocious induction of *mamo* transcription due to *chinmo-RNAi*. Instead, loss of Syp blocked the accumulation of mature *mamo* transcripts ([Figure 4I--K](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Meanwhile, without Syp the active sites of *mamo* transcription were short-lived, never surviving beyond the newborn neuron stage ([Figure 4I--K](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). These observations indicate that Syp is required post-transcriptionally for *mamo* mRNA maturation and sustained *mamo* transcription. This transcriptional maintenance may be due to positive feedback by the Mamo protein itself. Consistent with this notion, *mamo-RNAi* did not inhibit *mamo* induction in newborn neurons ([Figure 4L](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), but prevented *mamo* mRNA maturation and sustained *mamo* transcription ([Figure 4M](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).

![Syp promotes sustained *mamo* transcription.\
(**A**) Graphic illustrating the use of intron and exon probes for single molecule florescent in situ hybridization (smFISH). Nascent transcripts are labeled by both intron and exon probes, while mature transcripts are only labeled by exon probes. (**B**) Diagram illustrating interpretation of smFISH data. Active transcription is seen as a single, double-labeled focus per cell. Mature transcripts (magenta only) are diffuse and cytoplasmic. (**C--M**) smFISH with probes targeting *mamo* intronic (cyan) or exonic (magenta) sequences. Images are of developing larval brains with different genetic manipulations of the MB. Maximum Intensity Z-projections (2.3--3.8 μm) near the MB NB are shown. MB cells are determined by OK107 \>GFP (green dashed outline) and the newborn neuron (NN) region is outlined in white and the young/maturing neuron (YMN) region is outlined in yellow. Blue open arrows highlight examples of *mamo* active transcription, green arrows highlight examples of mature *mamo* transcripts. Images are representative of n \> 6. Scale bar = 5 μm. Control brains (*OK107 \>GFP*) show active transcription in NNs at 72 hr (**D**) and in NNs and young/maturing neurons at 84 hr (**E**). Mature transcripts are visible in young/maturing neurons at 84 hr ALH (**E**). *OK107* \>*chinmo-RNAi* results in a shift in the timing of *mamo* transcription. Active transcription is visible at 48 hr in both NNs and young/maturing neurons (**F**) and is abundant at 72 hr and 84 hr ALH (**G and H**). Note that MBs expressing *chinmo-RNAi* together with *Syp-RNAi* have active transcription in NNs at all time points, but lack mature transcripts and active transcription in young/maturing neurons (**I--K**). Depleting *mamo* (*OK107 \>mamo-RNAi*) causes loss of mature transcripts and active transcription in young neurons (**L--M**). The quantification of *mamo* mature transcripts is in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.\
10.7554/eLife.48056.016Figure 4---source data 1.Quantifications of mature *mamo* transcript.\
10.7554/eLife.48056.017Figure 4---source data 2.Intron and exon probe sequences.](elife-48056-fig4){#fig4}

Mamo is necessary for the middle α'/β' fate {#s2-4}
-------------------------------------------

Given Chinmo's role in specifying both γ and α'/β' neurons and in Mamo's expression in the middle, α'/β' temporal window, we hypothesize that Mamo is crucial for the specification of the α'/β' neuronal fate. To more accurately distinguish different neuronal types, we used a combination of FasII/Trio staining to examine MB neuronal projections and cell body markers (Abrupt and Trio) ([Figure 5A](#fig5){ref-type="fig"}). In keeping with our hypothesis, *mamo-RNAi* caused the α'/β' lobes to essentially vanish ([Figure 5C](#fig5){ref-type="fig"}). Wildtype α'/β' cell bodies characteristically express strong Trio, both in the cytoplasm and plasma membrane ([@bib3]) ([Figure 5B and B'](#fig5){ref-type="fig"}), whereas we detected little to no Trio expression in MB neurons expressing *mamo-RNAi* ([Figure 5C'](#fig5){ref-type="fig"}). This demonstrates a significant role for Mamo in proper α'/β' fate specification.

![Mamo is necessary and sufficient for the α'/β' fate.\
(**A**) Schematic of MB lobe morphology and table of corresponding marker expression. (**B--H**) Adult MB lobes (*OK107 \> GFP*) immunostained for GFP, Fas-II and Trio. Images are Z-stack projections of the axon region and are representative of n \> 18. Lobes are identified based on both 3D structure and marker expression. α'/β' lobes are outlined with orange dashed lines. Scale bar = 50 μm. Insert shows Trio staining alone. (**A'**) MB cell body markers that distinguish three MB neuron types. (**B'--H'**) Adult MB cell bodies (*OK107 \> GFP*) immunostained for Abrupt, Trio and GFP. GFP channel is not shown, but is represented by a green outline. Colored arrows highlight MB neuron types red=γ ( Trio^PM^/Abrupt^+^ ), orange=α'/β' (Trio^PM,Cyto^/Abrupt^-^), blue=α/β (Trio^-^/Abrupt^-^). Images are representative of n \> 6. A single focal plane is shown. Scale bar = 20 μm. Note wide Fas-II^++^ α/β lobes and a morphologically indistinct FasII weak/negative lobe (magenta arrows) with *mamo-RNAi* (**C**). *mamo-RNAi* and *chinmo-RNAi + mamo-RNAi* both lack most cell body marker staining (**C' and E'**). γ lobes and cell body markers are reduced in *chinmo-RNAi* alone (**D and D'**). Mamo overexpression (*mamo-GOF)* results in an expanded α'/β' lobe (**F**) and increased numbers of Trio^PM,Cyto^/Abrupt^-^ cell bodies (**F''**). Note the Fas-II^++^, Trio^-^ axons in the A/P (α), but not medial/lateral (β) portion of the axon lobe (blue arrow) which is surrounded by FasII^-/weak^, Trio^+^, morphologically indistinct axons (magenta arrow) in *mamo-GOF* (**F**). The cell body region is overwhelmingly Trio^+^ (**F'**). *Syp-RNAi* MB (**G and G'**) shows only γ neurons (note the A/P axon bundle characteristic of un-remodeled γ neurons). *Syp-RNAi* plus *mamo-GOF* produced expanded α'/β' lobes (**H**) and mostly Trio^PM,Cyto^/Abrupt^-^ cell bodies, with some Trio^PM^/Abrupt^+^ cells (**H'**). Note proliferating NBs (\*) and adjoining unspecified young/maturing neurons produced with *mamo-GOF* (**G' and H'**). The analysis of Mamo variants is in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}. The analysis of hierarchical model is in [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}. The quantification of neuron populations is in [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}.\
10.7554/eLife.48056.022Figure 5---source data 1.Quantification of adult MB neuron types.\
10.7554/eLife.48056.023Figure 5---source data 2.Intensity of Imp/Syp/Chinmo staining.](elife-48056-fig5){#fig5}

Nevertheless, Mamo may be pleiotropic, as the number of cells expressing the γ-specific marker, Abrupt, is also reduced ([Figure 5C'](#fig5){ref-type="fig"}). Examination of larval MB markers suggest that γ specification is normal (data not shown), signifying a distinct role for Mamo in γ neuron biology, which is being investigated separately. As γ lobe phenotypes complicate analysis of Mamo's role in α'/β' fate specification, we examined the role of Mamo in MBs after eliminating a majority of γ neurons with *chinmo-RNAi*. With premature weak Chinmo (*chinmo-RNAi*), γ neuron production significantly (p\<0.001) decreased from 38 ± 0.3% in control animals to 18 ± 1.6% with *chinmo-RNAi* ([Figure 5D and D'](#fig5){ref-type="fig"} and [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). This suggests an early onset of α'/β' neuron production and is consistent with the early Mamo transcription initiation at 48 hr ALH ([Figure 4F](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}) and early Mamo expression at 60 hr ALH ([Figure 2F](#fig2){ref-type="fig"}) that we detected with *chinmo-RNAi.* However, the percentage of α'/β' cells did not significantly increase. This suggests that with *chinmo-RNAi,* the window of α'/β' production was shifted earlier, rather than prolonged. The result is an increase in α/β neurons ([Figure 5D and D'](#fig5){ref-type="fig"} and [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). The percentage of α/β-characteristic Trio^-^/Abrupt^-^ cells increased from 41 ± 0.5% in control to 64 ± 1.1% with *chinmo-RNAi* [(]{.ul}p\<0.001). Strikingly, the combination of *mamo-RNAi* and *chinmo-RNAi* completely eliminated α'/β' neuronal features ([Figure 5E and E'](#fig5){ref-type="fig"}). This result substantiates an essential role for Mamo in α'/β' temporal fate determination.

Mamo variant functioning in α'/β' fate specification {#s2-5}
----------------------------------------------------

Next, we set out to determine which Mamo protein variant acts in α'/β' fate specification. The *mamo* gene has seven splice isoforms that produce four protein variants ([Figure 5---figure supplement 1A and B](#fig5s1){ref-type="fig"}). One variant contains only a BTB domain, and the remaining three have a BTB domain and three to five zinc finger motifs. We tested the three variants containing zinc fingers (codon optimized and lacking UTRs and introns) and found that only the Mamo variant with four zinc fingers (4ZF: corresponding to *mamo* isoforms RG and RF) produced MBs that were not reduced in size, but had reduced Fas-II labeling ([Figure 5---figure supplement 1C--F](#fig5s1){ref-type="fig"}), reminiscent of a shift in temporal fate specification. Importantly, we confirmed that the 4ZF Mamo construct could override the *mamo-*RNAi phenotype ([Figure 5---figure supplement 1G and H](#fig5s1){ref-type="fig"}). These data strongly indicate that either the *mamo-RF* or *mamo-RG* isoform lies downstream of Imp/Syp gradients and Chinmo in α'/β' temporal fate determination. In further support of a hierarchy, 4ZF Mamo overexpression does not alter Imp, Syp or Chinmo levels ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). The remainder of analyses in this paper were performed with the 4ZF Mamo transgene.

Mamo is sufficient to promote the middle α'/β' fate {#s2-6}
---------------------------------------------------

We next set out to determine whether Mamo could drive α'/β' neuronal fate outside of the middle developmental window. Continuous expression of transgenic Mamo greatly enlarged the α'/β' lobes and drastically reduced the thickness of the α/β lobes ([Figure 5F](#fig5){ref-type="fig"}), as determined by Trio and Fas-II expression. The reciprocal changes in Trio and Fas-II expression indicate an extension of α'/β' production into the pupal stage, when wildtype MB NBs produce α/β neurons. The alterations in the MB lobes are consistent with that of the cell body region which had enhanced and expanded Trio^PM,Cyto^ expression ([Figure 5F'](#fig5){ref-type="fig"} and [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}), denoting increased numbers of α'/β' neurons. The percentage of α'/β'-characteristic Trio^PM,Cyto^ expressing cells increased from 20 ± 0.8% in control to 32 ± 1.8% with *mamo-GOF* [(]{.ul}p\<0.005). Moreover, there was a concomitant reduction in Trio/Abrupt double negative α/β domains ([Figure 5F'](#fig5){ref-type="fig"} and [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). The percentage of α/β-characteristic Trio^-^ expressing cells decreased from 41 ± 0.5% in control to 2 ± 0.4% with *mamo-GOF* [(]{.ul}p\<0.001). Despite the lack of a clearly identifiable γ lobe, many of the cell bodies were Abrupt/Trio double positive ([Figure 5F'](#fig5){ref-type="fig"}, red arrow), leaving reservations about Mamo's ability to transform the early-born γ to α'/β' fate.

To definitively determine whether Mamo can transform γ neurons to the α'/β' fate, we over-expressed Mamo in MBs that would otherwise produce only γ neurons. We accomplished this using *Syp-RNAi* with which NBs do not appear to age ([@bib70]). As previously reported ([@bib70]), the *Syp-RNAi* expressing NBs cycled incessantly ([Figure 5G](#fig5){ref-type="fig"}, NBs marked with asterisks). Moreover, temporal progression stalled, producing only γ neurons, as determined by both lobe morphology and marker expression ([Figure 5G and G'](#fig5){ref-type="fig"}). The addition of transgenic Mamo caused the majority of neurons to assume the α'/β' fate ([Figure 5H and H'](#fig5){ref-type="fig"}). Importantly, this Mamo transgene does not contain UTRs or introns, thus it is not subject to post-transcriptional regulation. Note that Mamo overexpression did not alter the continued NB division ([Figure 5H'](#fig5){ref-type="fig"}, asterisks). These results confirm that Mamo is both necessary and sufficient to determine the middle α'/β' temporal fate. Taken together, our findings indicate that Mamo acts as a key temporal fate determinant for the α'/β' neuronal fate in the serial temporal fate diversification of MB neurons.

Mamo maintains α'/β' cell-fate {#s2-7}
------------------------------

As Mamo is essential for α'/β' neuronal fate specification and continues to be expressed in adult α'/β' neurons ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}), we wanted to examine whether it is required to maintain α'/β' cell fate. We utilized a temperature sensitive GAL80 ([@bib41]) to limit the expression of *mamo-RNAi* until after neuron fate was established. A temperature shift from 18°C to 29°C induced the expression of *mamo-RNAi* ([Figure 6A](#fig6){ref-type="fig"}). After adult eclosion, expression of *mamo-RNAi* for 21 days was required to effectively reduce Mamo protein levels ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). When Mamo was efficiently knocked down in adult MBs, the α'/β'-characteristic cytoplasmic Trio (Trio^Cyto,PM^/Abrupt^-^) was completely absent ([Figure 6C and C'](#fig6){ref-type="fig"}, 22 ± 1.6% control vs 0 ± 0% *mamo-RNAi*, p\<0.0005). The remaining membrane Trio expression (Tio^PM^/Abrupt^-^, 17 ± 2% of cells) may require a longer course of *mamo-RNAi* to be eliminated. These results clearly demonstrate that Mamo is required to maintain α'/β' cell-type specific Trio expression.

![Mamo maintains α'/β' MB neuron markers.\
(**A**) Scheme for temperature shift assay. Temperature-sensitive GAL80 was inactivated for 21 days after adult eclosion. E = embryo, L = larva, p=pupa, A = adult (**A'**) MB cell body marker expression of the three MB neuron types. (**B--D**) Adult MB cell bodies (*OK107 \> GFP+tub-GAL80ts*) immunostained for GFP, Abrupt, and Trio. Colored arrows identify MB neuron types based on marker expression: red=γ (Trio^PM^/Abrupt^+^), orange=α'/β' (Trio^PM,Cyto^ /Abrupt^-^), blue=α/β (Trio^-^/Abrupt^-^). Images are representative of n \> 6. A single focal plane is shown. Scale bar = 20 μm. Notice loss of cytoplasmic Trio staining after depleting expressing *mamo-RNAi* (**C and C'**, green arrows = Trio^PM^/Abrupt^-^ neurons). Overexpressing Mamo (*mamo-GOF)* after adult eclosion results in increased numbers of Trio^PM,Cyto^/Abrupt^-^ neurons (green filled area indicates MB calyx) (**D and D'**). (**E**) Percent of MB neurons expressing both cytoplasmic and plasma membrane Trio in orange (Trio^PM,Cyto^/Abrupt^-^) and percent of neurons expressing only plasma membrane Trio (Trio^PM^/Abrupt^-^) in green ﻿(mean ± SEM, n = 3 brains). Time course of Mamo depletion with adult induced RNAi is shown in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.\
10.7554/eLife.48056.027Figure 6---source data 1.Quantification of Trio expression (PM, Cyto).](elife-48056-fig6){#fig6}

Mamo stimulates α'/β' specific gene expression in mature MB neurons {#s2-8}
-------------------------------------------------------------------

To examine whether Mamo is sufficient to promote α'/β' fate transformation in mature MB neurons, we performed a similar experiment---overexpressing Mamo after neuron fate is established. We induced the expression of the 4ZF Mamo transgene by deactivating GAL80 with a temperature shift ([Figure 6A](#fig6){ref-type="fig"}). Overexpressing Mamo in adult MB neurons resulted in a modest, but significant increase in the percentage of cells with α'/β' characteristic gene expression (Trio^PM,Cyto^/Abrupt^-^, 22 ± 1.6% control vs 42 ± 4.1% *Mamo-GOF*, p=0.01; [Figure 6D and D'](#fig6){ref-type="fig"}). Markedly, the ability of Mamo overexpression to transform MB neurons diminished over time, as transgene induction at pupal development was more effective at increasing Trio^PM,Cyto^/Abrupt^-^ cells ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Taken together, our data suggests that Mamo acts as a terminal selector transcription factor for α'/β' neuronal fate, in part by regulating Trio gene expression.

Mamo is regulated by weak Chinmo and Syp in antennal lobe development {#s2-9}
---------------------------------------------------------------------

While the MB is a well-characterized lineage, with only three main temporal fates and constant NB division from embryonic through pupal stages, it is not necessarily typical. We therefore wanted to examine whether Mamo was downstream of Imp, Syp and Chinmo in other lineages. The AL lineages produce many more temporal fates over a shorter period of time (one AL NB produces 22 postembryonic fates). Interestingly, Imp and Syp temporal protein gradients show distinct lineage-characteristic expression levels and rates of gradient progression ([@bib36]; [@bib52]; [@bib63]). MB NBs have shallow, slowly progressing gradients and AL NBs have steep, rapidly progressing gradients ([@bib36]). We therefore examined Mamo in AL lineages defined by GR44F03-KD ([@bib4]). We found Mamo expression in at least two of the four labeled AL lineages at 84 hr ALH ([Figure 7D](#fig7){ref-type="fig"}). The defined temporal expression window leads us to believe that Mamo regulation by weak Chinmo and Syp may serve as a general mechanism for specifying temporal fate windows. To corroborate this idea, we monitored Chinmo and Mamo expression in AL lineages. We compared wildtype ALs with ALs expressing either *chinmo-RNAi* or both *chinmo-RNAi* and *Syp-RNAi*. Similar to our findings in the MB, weak Chinmo (*chinmo-RNAi*) induced precocious Mamo expression ([Figure 7B](#fig7){ref-type="fig"}) and an increase in the number of Mamo-positive neurons at 84 hr ALH ([Figure 7F](#fig7){ref-type="fig"}). Moreover, Mamo expression was lost when Syp was repressed ([Figure 7C and G](#fig7){ref-type="fig"}). These findings in the AL combined with our previous MB data leads us to a model where weak Chinmo and Syp specifically guide Mamo expression in defined temporal windows of diverse lineages ([Figure 8](#fig8){ref-type="fig"}).

![Weak Chinmo drives Mamo expression in AL lineages.\
Immunostaining for GFP (yellow), Mamo (magenta) and Chinmo (green) in AL lineages expressing *chinmo-RNAi*, *Syp-RNAi*, or dual *chinmo/Syp-RNAi*. Images are Z-stack projections (standard deviation) of the cell body region and are representative of n \> 10. Two AL lineages are outlined with yellow dashed lines based on GR44F03 lineage restricted actin \>GFP expression. GR44F03 lineage restricted actin-LexA also drives RNAi transgenes. Scale bar = 10 μm. The diagrams below summarize the protein levels of Mamo and Chinmo. (**A-C**) 72 hr ALH larval brains. Control brains have no visible Mamo staining within the AL lineages (**A**). Mamo staining is visible after reducing Chinmo levels with *chinmo-RNAi* (**B**). *chinmo-RNAi+Syp-RNAi* results in reduced Chinmo, but no Mamo expression (**C**). (**D-G**) 84 hr ALH. Control brains have Mamo positive cells in AL lineages (**D**). *Syp-RNAi* produces expanded Chinmo and loss of Mamo expression (**E**). *chinmo-RNAi* reduces Chinmo and increases the number of Mamo positive cells (**F**). *chinmo-RNAi + Syp-RNAi* results in weak Chinmo expression and loss of Mamo staining (**G**).](elife-48056-fig7){#fig7}

![Schematic of α'/β' neuronal fate determination.\
(**A**) Diagram of the three temporal windows of MB development. Images are color coded to illustrate the expression level of Imp (red) and Syp (blue). Chinmo (gray stars) and Mamo (green stars) levels are also indicated. (**B**) Hierarchical regulation of α'/β' neuronal fate determination. (1) Balance of Imp and Syp affects *chinmo* translation in the newborn neuron, producing low Chinmo levels ([@bib36]). (2) Low Chinmo levels initiate *mamo* transcription in the newborn neuron. (3) Syp promotes *mamo* mRNA maturation/stabilization during neuron maturation. (4) Mamo positively autoregulates its own expression. (5) Mamo promotes α'/β' specific gene expression in the mature neuron.](elife-48056-fig8){#fig8}

Discussion {#s3}
==========

Weak Chinmo on Mamo protein expression {#s3-1}
--------------------------------------

Chinmo levels in newborn neurons correlate with adult neuron identity ([@bib28]; [@bib73]). Based on smFISH, *mamo* transcription is initiated in newborn MB neurons around 72 hr ALH ([Figure 4D](#fig4){ref-type="fig"}), which corresponds to weak Chinmo expression ([Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}). Moreover, Mamo is only expressed when Chinmo levels are low, as Mamo is not expressed after either eliminating or overexpressing Chinmo ([Figure 2](#fig2){ref-type="fig"}). Together these data indicate that low Chinmo levels activate *mamo* transcription in young/maturing neurons.

Transcription initiation is not the only requirement for Mamo protein expression; Syp is also required ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}, discussed below). This could explain why we do not see Mamo expression turn on in γ neurons ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), even as they age and Chinmo levels decrease, becoming quite low around wandering larval stage ([@bib73]). γ neurons begin to express Mamo later, around pupation ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}), despite lacking Syp ([@bib36]). It has not yet been tested whether weak Chinmo levels are required for later Mamo expression in γ neurons. It is therefore possible that Mamo expression is controlled at this stage by an additional factor(s).

Chinmo, a potential morphogen {#s3-2}
-----------------------------

ChIP-chip performed in embryos found five Chinmo binding sites within the *mamo* gene ([@bib55]), consistent with direct activation of *mamo* transcription. However, the nature of Chinmo's concentration dependent actions is still unclear. Some morphogens such as Bicoid bind different targets at increasing concentrations based on the affinity of binding to different sites as well as the chromatin accessibility of the binding sites ([@bib17]). This may also be the case with Chinmo, but would not easily explain why Mamo expression is inhibited at higher Chinmo concentrations. The gap gene Krüpple, on the other hand, has concentration dependent activities at the same binding site. Krüpple acts as an activator at lower concentrations and as a repressor at high concentrations ([@bib56]). Krüpple's C-terminus has the ability to activate genes and is also the location for dimerization. Upon dimerization, the C-terminus can no longer activate genes and Krüpple transforms from an activator to a repressor ([@bib57]). Our data suggests that low concentrations of Chinmo activate *mamo*. However, in the testis, Chinmo is suspected to function as a transcriptional repressor ([@bib14]; [@bib16]). It is feasible that Chinmo, like Krüpple, could switch from an activator to a repressor. The protein concentration would affect whether Chinmo is a monomer (in the presence of other BTB proteins, a heterodimer) or a homodimer, and thus potentially which cofactors are recruited.

Syp stabilizes *mamo* transcripts {#s3-3}
---------------------------------

The ascending Syp RNA binding protein temporal gradient regulates Mamo expression both indirectly via its inhibition of Chinmo and also presumably directly, interacting with the *mamo* transcript and promoting its expression. The bi-modal, transcriptional (Chinmo) and post-transcriptional (Syp), regulation of the Mamo terminal selector is extremely advantageous. Given our finding that Mamo expression is positively autoregulated ([Figure 4L and M](#fig4){ref-type="fig"}) and that Mamo continues to be expressed into adult neurons ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}), it is particularly important to control the timing of Mamo's onset. The additional layer of post-transcriptional regulation adds an extra safeguard, helping to guarantee that neuronal temporal patterning is a robust system. Indeed, as brain development needs to adapt to environmental conditions such as nutrient deprivation, it is crucial to ensure that there is no loss of neuronal diversity ([@bib30]; [@bib35]).

Syp is a homolog of mammalian SYNCRIP (synaptotagmin-binding cytoplasmic RNA-interacting protein) also known as hnRNP-Q. SYNCRIP is involved with multiple facets of mRNA regulation including mRNA splicing and maturation ([@bib45]), mRNA localization and stabilization ([@bib5]) as well as inhibiting mRNA translation and miRNA-mediated repression via competition with Poly(A) binding proteins ([@bib62]). The *Drosophila* ortholog seems to have corresponding functions. *Drosophila* Syp was isolated from the spliceosome B complex, indicating a conserved role in mRNA splicing ([@bib18]). Syp has likewise been found to operate in mRNA localization and stabilization ([@bib39]). Furthermore, it has clear roles in altering protein expression of its mRNA targets, both positively and negatively ([@bib40]). The bidirectional influence on protein expression likely reflects different Syp modalities.

In this study, we show that Syp is required for Mamo protein expression in the MB and AL neuronal lineages ([Figures 3](#fig3){ref-type="fig"} and [7](#fig7){ref-type="fig"}). To determine the nature of this regulation, we performed smFISH ([Figure 4](#fig4){ref-type="fig"}). In the absence of Syp, *mamo* transcription was initiated prematurely in response to weak Chinmo levels, yet mature transcripts failed to accumulate ([Figure 4L--K](#fig4){ref-type="fig"}). This leads us to believe that Syp directly binds *mamo* mRNA and aids in its splicing, maturation and/or stabilization. This is consistent with our finding that overexpressing a *mamo* cDNA (lacking 5' UTR, 3' UTR and introns) was able to promote cell fate changes despite repression of Syp ([Figure 5H](#fig5){ref-type="fig"}).

Mamo is necessary and sufficient for α'/β' temporal fate {#s3-4}
--------------------------------------------------------

Mamo is required to produce the α'/β' neurons in the middle temporal window of the MB lineages. Trio positive α'/β' neurons are clearly absent after RNAi depletion of Mamo during development ([Figure 5C,C' and E,E'](#fig5){ref-type="fig"}). Cell production does not appear to be altered, as *mamo-RNAi* expressing MBs are a normal size. This begs the question of which, if any terminal fate the middle-born neurons adopt in the absence of Mamo. The limited markers for each MB cell type makes it difficult to determine whether the middle-born neurons undergo fate transformation or simply lack terminal fate. The presence of a Fas-II negative lobe ([Figure 5C](#fig5){ref-type="fig"}, magenta arrow) hints that some middle-born neurons may not carry temporal fate information, but phenotypic analysis is complicated by defects in γ neuron maturation/remodeling. Removing the γ neurons with *chinmo-RNAi* eliminates this complication, but it is still unclear whether, without Mamo, the neurons are transformed to the α/β fate ([Figure 5E and E'](#fig5){ref-type="fig"}). The Fas-II positive, α/β lobe appears enlarged ([Figure 5E](#fig5){ref-type="fig"}), but it is difficult to tell whether all axons are Fas-II positive or whether Fas-II negative axons are comingled with α/β axons. Without a cell type-specific, cell body marker for α/β neurons, it is ambiguous whether the middle-born cells are transformed to α/β or whether they simply lack α'/β' temporal fate. A transformation to α/β fate would suggest that either α/β is the default fate of MB neurons (requiring no additional terminal selector) or that Mamo expression inhibits α/β specific factors.

Mamo's role in promoting α'/β' fate is further supported by Mamo overexpression phenotypes. Overexpression of Mamo in the MB is able to transform α/β and γ neurons to α'/β' neurons ([Figure 5F,F', H and H'](#fig5){ref-type="fig"}). In an otherwise wildtype scenario, overexpression of *mamo* did not transform every cell to α'/β' fate ([Figure 5F](#fig5){ref-type="fig"}). Instead the α'/β' lobe was expanded and the other lobe seemed to be an amalgam of α and γ like lobes. This could be due to incomplete penetrance/low expression levels of the *mamo* transgene or it is possible that the α/β and γ cells retain their own terminal selector driven, cell-type specific gene expression, thus complicating the fate of the differentiated neuron. Mamo overexpression does not alter the specification factors Imp, Syp or Chinmo ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}) and presumably there are terminal selector genes expressed downstream of high Chinmo and possibly in Chinmo-absent cells. This seems a likely possibility when overexpressing Mamo in γ neurons. With *Syp-RNAi*, NBs are 'forever young' and divide into adulthood, persistently producing 'early-born' γ neurons. Interestingly when combining *Syp-RNAi* with the Mamo transgene, the newborn cells ([Figure 5H'](#fig5){ref-type="fig"}, cells adjacent to NBs) begin to take on a γ-like fate (expressing Abrupt) before a majority transform into an α'/β'-specific, strong Trio expression pattern and adopt α'/β'-like axon morphology. This suggests that Mamo functions downstream of the temporal fate specification genes, but is capable of overriding downstream signals in α/β and γ neurons to promote α'/β' terminal fate.

Mamo, a temporally patterned terminal selector gene {#s3-5}
---------------------------------------------------

What we describe about the BTB-ZF transcription factor, Mamo's role in α'/β' cell fate easily fits into the definition of a terminal selector gene, coined by Oliver Hobert ([@bib19]). Terminal selector genes are a category of 'master regulatory' transcription factors that control the specific terminal identity features of individual neuronal types ([@bib20]; [@bib19]). Key aspects of terminal selector genes are that they are expressed post-mitotically in neurons as they mature and they are continuously expressed (often via autoregulatory mechanisms) to maintain the terminal differentiated state of the neuron. Correspondingly, *mamo* transcription is initiated in newborn, post-mitotic neurons ([Figure 4D](#fig4){ref-type="fig"}) and Mamo protein expression is visible beginning in young/maturing neurons ([Figure 1C](#fig1){ref-type="fig"}). After transcription initiation, Mamo positively regulates its own expression ([Figure 4L and M](#fig4){ref-type="fig"}) and continues to be expressed in α'/β' neurons into adulthood ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). The other quintessential feature of terminal selector genes is that they regulate a battery of terminal differentiation genes, so that removing a terminal selector gene results in a loss of the specific identity features of a neuron type and misexpression can drive those features in other neurons ([@bib20]; [@bib19]). Indeed, removing Mamo with RNAi results in the loss of α'/β' identity, both developmentally ([Figure 5C and C', E and E'](#fig5){ref-type="fig"}) and into adulthood ([Figure 6C and C'](#fig6){ref-type="fig"}). Further, overexpressing Mamo in either α/β or γ MB neurons results in shift to α'/β' fate ([Figure 5F and F', H and H'](#fig5){ref-type="fig"}, [Figure 6D and D'](#fig6){ref-type="fig"}). Individual terminal selectors do not often function alone, but in combination with other terminal selectors. Therefore, there are likely terminal selectors downstream of the MB NB-specific genes that contribute to each of the MB neuron types. In this way, the lineage-specific and temporal patterning programs can combine to define individual neuron types. This feature enables the reutilization of terminal selector genes to create disparate neuron types when used in distinct combinations ([@bib20]). This further suggests that temporally expressed Mamo serves as a temporally defined terminal selector gene in other lineages, such as the AL lineages we describe here ([Figure 7](#fig7){ref-type="fig"}).

Temporal fating mechanism of Chinmo {#s3-6}
-----------------------------------

Altering Chinmo levels via upstream RNA-binding proteins ([@bib36]) or miRNAs ([@bib68]), or by reducing Chinmo with RNAi ([Figure 5D and D'](#fig5){ref-type="fig"} and [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}) all result in shifts in the ratio of neurons with different neuronal temporal fates. This evidence suggests a mechanism where Chinmo acts in newborn neurons to promote temporal fate specification. A recent publication suggested that Chinmo affects temporal fate via a neuronal remodeling mechanism by controlling Ecdysone signaling ([@bib38]). As in our first Chinmo study ([@bib73]), Marchetti and Tavosanis demonstrate that Chinmo is required for EcR-B1 expression; however it remains unclear whether Chinmo directly affects EcR-B1 expression or if the Chinmo-dependent EcR-B1 expression is the sole mechanism for γ neuron temporal fate specification. Moreover, neuronal temporal fate is not accurately determined by neuronal morphology alone, particularly when ecdysone signaling has known effects on MB cell morphology ([@bib32]) and fate ([@bib29]). Ecdysone receptor signaling is highly pleiotropic ([@bib2]), including ligand-independent functions ([@bib44]) making dominant-negative and overexpression studies difficult to interpret. Therefore, further investigation is needed to clarify the roles of Ecdysone receptor signaling in MB neuronal temporal fate and remodeling. We hope to address this in a follow-up paper. This current manuscript strongly promotes the idea that Chinmo functions in newborn neurons to promote temporal fate as weak Chinmo expression ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) directly precedes Mamo transcription ([Figure 4](#fig4){ref-type="fig"}) and Mamo is essential for specification ([Figure 5](#fig5){ref-type="fig"}) and maintenance of α'/β' fate ([Figure 6](#fig6){ref-type="fig"}).

Evolutionary conservation {#s3-7}
-------------------------

We describe a multilayered hierarchical system to define distinct neuronal temporal fate that culminates in the expression of a terminal selector gene. Analogous mechanisms likely underlie temporal patterning in mammalian brains. However, whether orthologous genes play equivalent roles in mammalian temporal patterning has not been fully investigated. The Imp and Syp RNA-binding proteins are evolutionarily conserved. Both homologs are highly expressed in the developing mouse brain and play vital roles in neural development and/or neuronal morphology ([@bib9]; [@bib43]; [@bib50]; [@bib67]; [@bib69]). The opposing functions of Imp and Syp also appear to be conserved, as the murine orthologs IMP1 and SYNCRIP bind the identical RNA to either promote ([@bib13]) or repress axon growth ([@bib67]), respectively. Moreover, IMP1 expression in fetal mouse neural stem cells plays important roles in stem cell maintenance and proper temporal progression of neurogenesis. It would likewise be very interesting to explore SYNCRIP in the context of temporal patterning.

While Chinmo and Mamo have no clear mammalian orthologs, they are both BTB-ZF (broad-complex, tram-track and bric-à-brac - zinc finger) transcription factors ([@bib46]; [@bib73]). The BTB domain is a protein interaction domain that can form homo or heterodimers and also binds transcriptional regulators such as repressors, activators and chromatin remodelers ([@bib49]). The C~2~H~2~ (Krüppel-like) zinc fingers bind DNA---providing target specificity. BTB-ZF proteins have been found to be critical regulators of developmental processes, including neural development ([@bib8]; [@bib59]). Indeed, the BTB-zinc finger protein, Zbtb20, appears to be essential for early-to-late neuronal identity in the mouse cortex ([@bib65]). Zbtb20 is temporally expressed in cortical progenitors and knockout results in cortical layering defects ([@bib65]), as the inside-out layering of the cortex follows neuronal birth order. While mutations of other brain-expressed BTB-ZF proteins also show cortical layering phenotypes ([@bib7]; [@bib48]), potential roles in temporal patterning have not been explored.

Conclusions {#s3-8}
-----------

In this study, we illustrate a fate specification process in which a layered series of temporal protein gradients guide the expression of terminal selector genes. The first-tier temporal gradients are expressed in neural stem cells, followed by a restricted expression window in newborn neurons to finally induce a terminal selector gene in a subset of neurons as they mature. This time-based subdivision of neuronal fate can likely be further partitioned, finally resulting in sequentially born neurons with distinct cell fates. We demonstrate that Mamo, a BTB-ZF transcription factor, delineates α'/β' neurons, the middle temporal window of the MB lineages. Corresponding data in the AL lineages suggest that Mamo may serve as a temporally defined, terminal selector gene in a variety of lineages in the *Drosophila* brain. Mamo expression is regulated transcriptionally by the descending Chinmo BTB-ZF transcription factor gradient and post-transcriptionally by the Syp RNA binding protein. This multi-tiered, bimodal regulation ensures that only the progeny in a precise temporal window (those with both weak Chinmo and significant Syp levels) can effectively activate the terminal selector gene, *mamo*. This discovery attests to the power of gradients in creating diverse cells from a single progenitor. Utilizing layers of temporal gradients to define discrete temporal windows mirrors how in early embryos the spatial gradients of RNA-binding proteins and transcription factors specify the fly's A/P axis. This paradigm provides considerable complexity of gene network regulation, leading to abundant neural cell diversity.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                         Designation                                                                                         Source or reference                           Identifiers                                                                               Additional\
  (species) or resource                                                                                                                                                                                                                                                             information
  ------------------------------------- --------------------------------------------------------------------------------------------------- --------------------------------------------- ----------------------------------------------------------------------------------------- -------------------------------------------------------------
  Antibody                              anti-Mamo (Rabbit polyclonal)                                                                       This paper: Materials and methods                                                                                                       (1:1000), Lee T, Janelina Research Campus, HHMI

  Antibody                              anti-GFP, Alexa488\                                                                                 Thermo Fisher Scientific                      Cat \# A-21311; RRID:[AB_221477](https://scicrunch.org/resolver/AB_221477)                (1:1000)
                                        (Rabbit polyclonal)                                                                                                                                                                                                                         

  Antibody                              anti-GFP (Chicken polyclonal)                                                                       Thermo Fisher Scientific                      Cat \# A10262; RRID:[AB_2534023](https://scicrunch.org/resolver/AB_2534023)               (1:1000)

  Antibody                              anti-Chinmo (Rabbit polyclonal)                                                                     [@bib73]                                                                                                                                (1:1000)

  Antibody                              anti-Chinmo (Rat)                                                                                   [@bib68]                                                                                                                                (1:500)

  Antibody                              anti-Trio (Rabbit)                                                                                  [@bib3]                                                                                                                                 (1:1000)

  Antibody                              anti-Abrupt (Rabbit)                                                                                [@bib22]                                                                                                                                (1:200)

  Antibody                              anti-Imp (Rabbit)                                                                                   gift from Paul Macdonald                                                                                                                (1:600)

  Antibody                              anti-Syp (Genia pig)                                                                                gift from Ilan Davis                                                                                                                    (1:500)

  Antibody                              anti-Trio (Mouse monoclonal)                                                                        Developmental Studies Hybridoma Bank          9.4A;Registry ID:AB_528494                                                                (1:200)

  Antibody                              anti-Fas-II (Mouse monoclonal)                                                                      Developmental Studies Hybridoma Bank          1D4; Registry ID:AB_528235                                                                (1:40)

  Antibody                              anti-nc82 (Mouse monoclonal)                                                                        Developmental Studies Hybridoma Bank          nc82; Registry ID:AB_2314866                                                              (1:100)

  Antibody                              anti-chicken, Alexa488 (Goat)                                                                       Thermo Fisher Scientific                      Cat \# A-11039; RRID:[AB_2534096](https://scicrunch.org/resolver/AB_2534096)              (1;500)

  Antibody                              anti-mouse, Alexa568 (Goat)                                                                         Thermo Fisher Scientific                      Cat \# A-11031; RRID:[AB_144696](https://scicrunch.org/resolver/AB_144696)                (1;500)

  Antibody                              anti-rabbit, Alexa647 (Goat)                                                                        Thermo Fisher Scientific                      Cat \# A-21244; RRID:[AB_2535812](https://scicrunch.org/resolver/AB_2535812)              (1;500)

  Antibody                              anti-Rat, Alexa568 (Goat)                                                                           Thermo Fisher Scientific                      Cat \# A-11077; RRID:[AB_2534121](https://scicrunch.org/resolver/AB_2534121)              (1;500)

  Antibody                              anti-rabbit, Alexa568 (Goat)                                                                        Thermo Fisher Scientific                      Cat \# A-11036; RRID:[AB_10563566](https://scicrunch.org/resolver/AB_10563566)            (1;500)

  Antibody                              anti-mouse, Alexa647 (Donkey)                                                                       Jackson ImmunoResearch lab, Inc.              Cat \# 715-605-151                                                                        (1;500)

  Antibody                              anti-Rat, DyLight405 (Goat)                                                                         Jackson ImmunoResearch lab, Inc.              Cat \# 112-475-167                                                                        (1;200)

  Chemical compound, drug               Paraformadehyde20% Solution, EM Grade                                                               Electron Microscopy Sciences                  Cat \# 15713                                                                              

  Chemical compound, drug               Phosphate Buffered Saline 10X,Molecular Biology Grade                                               Thermo Fisher Scientific                      Cat \# 46--013 CM                                                                         

  Chemical compound, drug               Triton X-100                                                                                        Sigma-Aldrich                                 Cat \# 329830772                                                                          

  Chemical compound, drug               SlowFadeTM Gold antifade Mountant                                                                   Thermo Fisher Scientific                      Cat \# S36936                                                                             

  Chemical compound, drug               RNase-free 1x PBS                                                                                   Thermo Fisher Scientific                      Cat \# BP2438-4                                                                           

  Chemical compound, drug               Acetic Acid, Glacial                                                                                Thermo Fisher Scientific                      Cat \# A38S-500                                                                           

  Chemical compound, drug               Sodium borohydride                                                                                  Acros Organics/Thermo Fisher Scientific       Cat \# AC448481000                                                                        

  Chemical compound, drug               Invitrogen SSC (20X)                                                                                Thermo Fisher Scientific                      Cat \# AM9763                                                                             

  Chemical compound, drug               Hi-Di formamide                                                                                     Applied Biosystems/Thermo Fisher Scientific   Cat \# 4311320                                                                            

  Chemical compound, drug               Alfa Aesar Denhardt\'s solution (50X)                                                               Alfa Aesar/Thermo Fisher Scientific           Cat \# AAJ63135AD                                                                         

  Chemical compound, drug               tRNA from Baker\'s yeast                                                                            Roche                                         Cat \# 10109495001                                                                        

  Chemical compound, drug               UltraPure Salmon Sperm DNA Solution                                                                 Thermo Fisher Scientific                      Cat \# 15632011                                                                           

  Chemical compound, drug               Corning 10% SDS                                                                                     Corning/Thermo Fisher Scientific              Cat \# 46--040 CI                                                                         

  Chemical compound, drug               Deionized formamide                                                                                 Ambion/Thermo Fisher Scientific               Cat \# AM9342                                                                             

  Chemical compound, drug               RNase*Zap* RNase Decontamination Solution                                                           Thermo Fisher Scientific                      Cat \# AM9780                                                                             

  Chemical compound, drug               Poly-L-lysine hydrobromide                                                                          Sigma-Aldrich                                 Cat \# P1524-25MG                                                                         

  Chemical compound, drug               Cy3 Mono-Reactive Dye Pack                                                                          GE Healthcare Life Sciences                   Cat \# PA23001                                                                            

  Chemical compound, drug               Cy5 Mono-Reactive Dye Pack                                                                          GE Healthcare Life Sciences                   Cat \# PA25001                                                                            

  Chemical compound, drug               Ethyl alcohol, pure                                                                                 Sigma-Aldrich                                 Cat \# 459844                                                                             

  Chemical compound, drug               Xylenes                                                                                             Thermo Fisher Scientific                      Cat \# X5-500                                                                             

  Chemical compound, drug               DPX mountant                                                                                        Electron Microscopy Sciences                  Cat \# 13512                                                                              

  Genetic reagent (*D. melanogaster*)   *tub-Gal80ts*                                                                                       Bloomington *Drosophila* stock center         BDSC:7018; FLYB:FBst0007018; RRID:[BDSC_7018](https://scicrunch.org/resolver/BDSC_7018)   FlyBase symbol:P{w\[+mC\]=tubP-GAL80\[ts\]}ncd\[GAL80ts-7\]

  Genetic reagent (*D. melanogaster*)   *UAS-Syp-RNAi*                                                                                      Vienna *Drosophila* RNAi Center               VDRC:v33012; FLYB:FBst0459886                                                             FlyBase symbol: P{GD9477}v33012

  Genetic reagent (*D. melanogaster*)   *UAS-mamo-RNAi*                                                                                     Bloomington *Drosophila* stock center         BDSC:51770; FBti0157732; RRID:[BDSC_51770](https://scicrunch.org/resolver/BDSC_51770)     FlyBase symbol:P{TRiP.HMC03325}attP40

  Genetic reagent (*D. melanogaster*)   *UAS-mamo-RNAi*                                                                                     Bloomington *Drosophila* stock center         BDSC: 44103; FBti0158705; RRID:[BDSC_44103](https://scicrunch.org/resolver/BDSC_44103)    FlyBase symbol:P{TRiP.HMS02823}attP40

  Genetic reagent (*D. melanogaster*)   *UAS-mCD8-GFP; +; GAL4-OK107*                                                                       [@bib10]                                                                                                                                

  Genetic reagent (*D. melanogaster*)   *UAS-chinmo-RNAi*                                                                                   [@bib36]                                                                                                                                

  Genetic reagent (*D. melanogaster*)   *UAS-chinmo-GOF (UAS-chinmo-3UTR)*                                                                  [@bib73]                                                                                                                                

  Genetic reagent (*D. melanogaster*)   *UAS-Syp-GOF*                                                                                       [@bib36]                                                                                                                                

  Genetic reagent (*D. melanogaster*)   *UAS-mamo-3ZFs-GOF*                                                                                 [@bib46]                                                                                                                                

  Genetic reagent (*D. melanogaster*)   *UAS-mamo-4ZFs-GOF*                                                                                 This paper: Materials and methods                                                                                                       Lee T, Janelina Research Campus, HHMI

  Genetic reagent (*D. melanogaster*)   *UAS-mamo-5ZFs-GOF*                                                                                 This paper: Materials and methods                                                                                                       Lee T, Janelina Research Campus, HHMI

  Genetic reagent (*D. melanogaster*)   *Dpn \> KDRT-stop-KDRT\>Cre PEST; act \> loxP-stop-loxP\>LexA::P65, lexAop2-myr::GFP; GR44F03-KD*   [@bib4]                                                                                                                                 

  Genetic reagent (*D. melanogaster*)   *LexAop2-chinmo-RNAi*                                                                               This paper: Materials and methods                                                                                                       Lee T, Janelina Research Campus, HHMI

  Genetic reagent (*D. melanogaster*)   *LexAop2-Syp-RNAi*                                                                                  [@bib52]                                                                                                                                

  Genetic reagent (*D. melanogaster*)   *UAS-mCD8-GFP-insu-UAS-rCD2-RNAi, chinmo1, FRT40A*                                                  [@bib28]                                                                                                                                

  Genetic reagent (*D. melanogaster*)   *hs-FLPop; tub-GAL80, FRT40A; +; GAL4-OK107*                                                        This paper: Materials and methods                                                                                                       Lee T, Janelina Research Campus, HHMI

  Software, algorithm                   Fiji                                                                                                NIH; [@bib58]                                 <https://fiji.sc/>                                                                        

  Software, algorithm                   Adobe Photoshop                                                                                     Adobe Systems, San Jose, CA                   <https://www.adobe.com/products/photoshop.html>                                           

  Software, algorithm                   Adobe Illustrator                                                                                   Adobe Systems, San Jose, CA                   <https://www.adobe.com/products/illustrator.html>                                         

  Software, algorithm                   Python                                                                                              Python Software Foundation                    <https://www.python.org/>                                                                 

  Software, algorithm                   Flybase 2.0                                                                                         [@bib64]                                      <http://flybase.org>                                                                      

  Software,\                            Matplotlib                                                                                          [@bib23]                                      <https://matplotlib.org>                                                                  
  algorithm                                                                                                                                                                                                                                                                         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All strains of the *Drosophila melanogaster* used in this study were listed below. Stocks were raised at 25°C incubator.

For labeling entire MB lineages, we used *UAS-mCD8-GFP; +; GAL4-OK107* ([@bib10]). For temperature shift assay, we used a temperature sensitive GAL80 ([@bib41]). The following transgenenic flies were used. (1) *UAS-Syp-RNAi* (stock\# 33012, VDRC stock center), (2) *UAS-mamo-RNAi* (stock\# 51770 and \# 44103, Bloomington stock center), (3) *UAS-chinmo-RNAi* ([@bib36]), (4) *UAS-chinmo-GOF* (*UAS-chinmo-3UTR*; [@bib73]), (5) *UAS-Syp-GOF* ([@bib36]), (6) *UAS-mamo-3ZFs-GOF* ([@bib46]), (7) *UAS-mamo-4ZFs-GOF* (this study), (8) *UAS-mamo-5ZFs-GOF* (this study).

For labeling AL lineages, we used *Dpn \> KDRT-stop-KDRT\>Cre PEST; act \>loxP-stop-loxP\>LexA::P65, lexAop2-myr::GFP; GR44F03-KD* ([@bib4]). The following transgenic flies were used. (1) *LexAop2-chinmo-RNAi* (this work) (2) *LexAop2-Syp-RNAi* ([@bib52]).

To generate *chinmo* mutant MARCM clones, *UAS-mCD8GFP-insu-UAS-rCD2-RNAi, chinmo^1^, FRT40A* flies ([@bib28]) were crossed with *hs-FLPop; tub-GAL80, FRT40A; +; GAL4-OK107* flie*s*. The crossed flies laid eggs in the vials for every four hours. MARCM clones were induced at newly hatched larvae (NHL) via heat shock at 37°C for 30 mins and dissected at 84 hr ALH.

To express *mamo-GOF (3ZFs, 4ZFs, 5ZFs)*, we made *UAS-mamo-GOF (4ZFs, 5ZFs)* flies. The driver *GAL4-OK107* was utilized for driver dependent ectopic induction of the isoform *mamo-3ZFs, mamo-4ZFs*, and *mamo-5ZFs.*

﻿Temporal induction of RNAi and Overexpression after adult eclosion {#s4-1}
-------------------------------------------------------------------

Embryo with genotype *UAS-mamo-RNAi/UAS-GFP; tub-GAL80ts/OK107 Gal4* or *UAS-mamo-GOF/UAS-GFP; tub-GAL80ts/OK107 Gal4* were cultured at 18°C until adult eclosion. The Adult were incubated at 29°C to inactivate the temperature-sensitive GAL80 and cultured for 7 days or 21 days. The Adult were dissected right after the culture.

﻿Temporal induction of Overexpression after pupal stage {#s4-2}
-------------------------------------------------------

Embryo with genotype *UAS-mamo-GOF/UAS-GFP; tub-GAL80ts/OK107 Gal4* were cultured at 18°C until white pupae. The white pupae were collected and cultured at 18°C for 2 days. Then, they were incubated at 29°C to inactivate the temperature- sensitive GAL80 and cultured for 7 days. The Adult were dissected right after the culture.

Antibodies and immunostaining {#s4-3}
-----------------------------

Fly brains at specific developmental stages were dissected in the 1X Phosphate Buffered Saline (PBS, Thermo Fisher Scientific). After brains were fixed in 4% paraformaldehyde (Electron Microscopy Sciences) for 35mins, they were wash in 0.5% PBT (1X PBS with 0.5% Trioton X-100, Sigma-Aldrich) for three times and immunostained for primary antibodies for overnight as described previously ([@bib34]). The brains were washed in 0.5% PBT and immunostained for secondary antibodies for overnight. The next day, the brains were washed and mounted in SlowFade Gold antifade Mountant (Thermo Fisher Scientific). The following primary antibodies were used: chicken anti-GFP (1:1000, A10262, Life Technologies), rabbit anti-Mamo (1:1000, this study), rabbit anti-Chinmo (1:1000, [@bib73]), rat anti-Chinmo (1:500, [@bib68]), rabbit anti-Trio (1:1000, ([@bib3]), mouse anti-Trio (1:200, 9.4A, Developmental Studies Hybridoma Bank), mouse anti-Fas-II (1:40, 1D4, Developmental Studies Hybridoma Bank), rabbit anti-Abrupt (1:200, [@bib22]), Rabbit anti-Imp (1:600, gift from Paul Macdonald, University of Texas at Austin) and Genia pig anti-Syp (1:500, gift from Ilan Davis, University of Oxford). All corresponding fluorescent secondary antibodies (1:500) were purchased from Life Technologies. Images of whole-mount fly brains were acquired using a Zeiss LSM 710 or LSM 880 confocal microscope and processed with Fiji-Image J and Adobe Photoshop.

Antibody generation {#s4-4}
-------------------

The polyclonal rabbit anti-Mamo antibody was raised against the QKREASDRSSPTPAC peptide (aa 273 to aa 286 in Mamo, GenScript).

Molecular biology {#s4-5}
-----------------

To generate miRNA construct for *chinmo*, two polycistronic transcripts that each encoding two miRNAs against *chinmo*. The miRNA targeting sequences were 5'- ACAGAGATACGGACAAAGATAC-3' and 5'-CATCTACCGGCCTATTAACTAC-3'. The above transcripts were inserted after the lexAop promoter in the pMLH Plasmid ([@bib51]). The restriction enzyme sites used were 5'-NotI to 3'-XhoI.

To generate different isoforms of *mamo*, full-length DNA sequence of *mamo-4ZFs* and C-terminal sequence of *mamo-5ZFs* were obtained from flybase. Two DNA fragments were synthesized by GenScript. The fragment of *mamo-4ZFs* was flanked by XhoI and XbaI. To generate the fragment of *mamo-5ZFs*, the C-terminus of *mamo-4ZFs* was replaced by the C-terminus of *mamo-5ZFs*, which was following a single cut with Bgl-II. Both full-length fragments of *mamo-4ZFs* and *mamo-5ZFs* were insert into XhoI/XbaI site to replace B3::PEST in pJFRC157-20XUAS-IVS-B3::PEST vector (Addgene plasmid 32136).

The plasmid of *LexAop2-chinmo-RNAi*, *UAS-mamo-4ZFs-GOF* and *UAS-mamo-5ZFs-GOF* was injected by Rainbow Transgenic Flies, Inc (Camarillo,CA,USA). The complete nucleotide sequences of the plasmids will be provided upon request.

smFISH {#s4-6}
------

The detailed FISH methods, probe design and labeling protocols were as described previously ([@bib37]). FISH probe sequences for *mamo* nascent and mature transcripts are listed in [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}. The amino modified FISH probes targeting nascent and mature *mamo* transcripts were coupled to Cy3 and Cy5 fluorophores through N-hydroxysuccinimide esters. Fly brains at specific developmental stages were dissected in 1xPBS and fixed in 4% paraformaldehyde at room temperature for 35 min. Tissues were washed in 0.5% PBT, dehydrated, and stored in 100% ethanol at 4°C overnight. After rehydration in the following day, tissues were incubated in 5% acetic acid at 4°C for 5 min and fixed in 2% paraformaldehyde in for 35 min at 25°C. Fly brains were then washed in 1 × PBS containing 1% of NaBH4 at 4°C for 30 min. After a 2 hr incubation in prehybridization buffer (15% formamide, 2 × SSC, 0.1% Triton X-100) at 50°C, fly brains were introduced to hybridization buffer (10% formamide, 2 × SSC, 5 × Denhardt\'s solution, 1 mg/ml yeast tRNA, 100 μg/ml, salmon sperm DNA, 0.1% SDS) with FISH probes, and incubation at 50°C for 10 hr and then at 37°C for an additional 10 hr. Fly brains were washed in a series of washing solutions, dehydrated, cleared in xylene, and mounted in DPX. The confocal images were collected using Zeiss LSM 880 and processed with Fiji-Image J and Adobe Photoshop after the tissues were cured for 24 hr.

Image analysis {#s4-7}
--------------

To measure Chinmo, Mamo, Imp, Syp signal intensity in the MB ([Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"}, [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}), the NBs, newborn neurons and maturing neurons were labeled with OK107-Gal4 \> GFP. The definition of newborn and maturing neurons was based on the GFP intensity as described in the [Figure 1](#fig1){ref-type="fig"} legend. We selectively analyzed white and yellow outlines at the chosen focal planes near the NB region. For NB, we selectively analyzed those NBs (circled) with a maximum diameter. To compare Chinmo ([Figure 1](#fig1){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}), Mamo ([Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"}) and Imp/Syp ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}) levels across various genotypes, the samples were immunostained simultaneously for every single experiment. The images were taken using the same confocal setting (pinhole size, gain, laser power, etc.) and an image of selected focal plane was exported to Adobe Photoshop. A hand-drawn mask was created for the newborn neurons (for Chinmo), the maturing neurons (for Mamo) and the cytoplasmic (for Imp/Syp) region of interest at selected focal plane. The averaged grayscale value for each pre-defined region was calculated using the 'Histograms' algorithm in Photoshop. The grayscale values of Chinmo and Mamo and Imp/Syp were normalized to the background staining in the developing central brains.

Genomic {#s4-8}
-------

The mamo isoform transcription start site (TSS) and exons are extracted from Flybase annotation (dmel-all-r6.17.gtf). Protein domain information is obtained from uniprot (<http://www.uniprot.org>; Q9VY72 for RH, RI; M9NEG1 for RF, RG; M9PJM9 for RD, RE; H1UUK0 for RC isoforms). In house custom program in Python (<http://www.python.org>) with matplotlib (<http://www.matplotlib.org>) library is used to make the gene structure diagram.

Quantification and statistical analysis {#s4-9}
---------------------------------------

Quantification of Mamo positive neurons in fly brains in [Figure 2](#fig2){ref-type="fig"} was analyzed with Student's t test. Sample size and *P values* are mentioned within the figure legend and [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}.

Data and software availability {#s4-10}
------------------------------

Customized MATLAB and Python scripts used in this paper are in the [Source code 1](#scode1){ref-type="supplementary-material"}.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Mamo decodes hierarchical temporal gradients into terminal neuronal fate\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by Oliver Hobert as the Reviewing Editor and K VijayRaghavan as the Senior Editor. Chris Doe has agreed to reveal his identity as one of the reviewers.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

This manuscript describes Mamo as an interesting new factor that controls the ordered birth of different neuron types during neurogenesis. The fact that it is expressed in both the mushroom body and in antennal lobe lineages further suggests that it is a general temporal factor and not lineage specific. It is therefore a significant finding that deserves to be published. However, prior to publication, the authors need to (a) extend their analysis (with some very simple and doable experiments) and (b) clarify a number of points.

The two set of experiments required to deepen their analysis are:

1\) Remove Mamo from adults and assay Kenyon cell fate and function. Again, technically trivial (OK107-Gal4, Gal80.ts, *UAS-mamo-RNAi*) and would help solidify the conclusion that Mamo is a terminal selector gene. Similarly, misexpress Mamo in specifically in adults (OK107-Gal4, Gal80.ts, *UAS-mamo-GOF*) and assay for ectopic a\'/b\' neurons.

2\) Overexpress constitutive Mamo (replace UTRs) and assay for Imp, Syp, and Chinmo. All three should have normal expression patterns if the hierarchical regulation model is true. This is technically trivial, and the *mamo* construct is even mentioned in the Discussion (although incorrectly cited as being in Figure 4L, which is a different experiment).

In addition, the following additional points need to be clarified:

I\) They need to quantity the number of neurons present/missing in the different genetic backgrounds. This can be done either using the markers the authors describe in the manuscript, or using cell-type specific Gal4/LexA lines. A general question that arises throughout the manuscript is to address the fate of neurons born in different temporal windows when Chinmo, Mamo, Imp or Syp are missing.

II\) They also need to clearly indicate in all figures newborn vs. maturing vs. mature neurons. An outline around the different neuron populations (i.e., newborn vs. mature) would make it easier to understand the different expression domains.

III\) Finally, the authors need to quantify fluorescence intensity values for Chinmo and Mamo in control and all mutant backgrounds.

In more detail:

\- In Figure 1, the authors use OK107-Gal4 to label mushroom body neurons. According to Figure 1A, this driver labels more than 1 neuron type in the mushroom bodies after 72 hrs. Thus, it is not possible to determine whether the Mamo positive staining in 1C is in γ neurons or in α\'β\' neurons, particularly since maturing vs. newborn neurons is not clearly defined. The authors need to do the same staining using either a γ-Gal4 line (e.g., 201y-Gal4 or 71G10-Gal4) or an α'β'-Gal4 line.

\- Similar to the above comment, the authors need to determine which mushroom body cells are Mamo positive in Figure 1D. At this stage, all three mushroom neuron types are present. Do all neuron types eventually become Mamo positive? For example, since Chinmo is not maintained, does Mamo become activated in all cells that once expressed Chinmo once Chinmo levels decline (as shown in Figure 1D)? If so, it would help validate part of the authors model that low Chinmo activates Mamo. The authors need to use Gal4 lines that label the different mushroom body neuron types and stain/quantify Mamo and Chinmo levels during development.

\- Chinmo and Mamo levels should be quantified in newborn/maturing/mature neurons through time in Figure 1B-D.

\- Quantify Chinmo levels at 84 ALH in Figure 2. It is not enough to place stars in the cartoon, especially since the authors want to show that low Chinmo activates Mamo. At 48h ALH, in Figure 3---figure supplement 1D, Chinmo levels already look undetectable. This is a major point of the paper that should be better characterized/quantified.

\- In Figure 2D, the authors need to define what the additional Mamo positive neurons are within the clones. Are they γ neurons (they have low Chinmo, and so they might activate Mamo), or are they additional α'β' neurons specified earlier? The same is true for Figure 2F. Given the context of the manuscript, it is assumed that they are additional α'β' neurons but the authors need to demonstrate this point and state clearly their conclusion.

\- In Figure 3D, Mamo expression is lost at 84 ALH. However, the authors have previously reported (Lee, Science) that overexpression of Imp or Syp leads to additional α'β' neurons in the adult, while later in this manuscript, they demonstrate that Mamo is necessary for α'β' identity. Thus, the authors should put their new findings in context of their previous results. When are additional α'β' neurons born according to their current model? In the pupal window?

\- For Figure 4, the authors need to quantify the smFISH results. For example, it is difficult to know if there is a difference in mature transcript abundance between 4M and 4H. They must show the smFISH results in a Syp-RNAi background alone (They do show Syp-RNAi with Chinmo RNAi).

\- Figure 5H: Syp-RNAi with *Mamo-GOF* results in a mushroom body with a majority of α'β' neurons. However, throughout the manuscript, the authors have made a point to indicate that Mamo requires post-transcriptional regulation by Syp. Thus, this result seems to contradict the authors\' earlier results as *Mamo-GOF* should not lead to additional α'β' neurons in the absence of Syp. This apparent discrepancy must be addressed.

\- The authors must quantify the number of α'β' neurons in the different genetic backgrounds in Figure 5 (e.g. using strong Trio expression of more than one marker.

10.7554/eLife.48056.034

Author response

> This manuscript describes Mamo as an interesting new factor that controls the ordered birth of different neuron types during neurogenesis. The fact that it is expressed in both the mushroom body and in antennal lobe lineages further suggests that it is a general temporal factor and not lineage specific. It is therefore a significant finding that deserves to be published. However, prior to publication, the authors need to (a) extend their analysis (with some very simple and doable experiments) and (b) clarify a number of points.
>
> The two set of experiments required to deepen their analysis are:
>
> 1\) Remove Mamo from adults and assay Kenyon cell fate and function. Again, technically trivial (OK107-Gal4, Gal80.ts, UAS-mamo-RNAi) and would help solidify the conclusion that Mamo is a terminal selector gene.

We have included a new Figure (Figure 6), supplementary figures (Figure 6---figure supplements 1 and 2) and a new section in the Results (Mamo maintains α'/β' cell-fate) to help address Mamo's role in maintenance of α'/β' neuronal fate. *Mamo-RNAi* induction in adult mushroom body neurons caused a progressive reduction in Trio expression. *Mamo-RNAi* was very slow to reduce Mamo levels; after one week of expressing *mamo-RNAi*, Mamo protein still remained. This may have been due to strong positive autoregulation of Mamo expression. After three weeks of RNAi, Mamo protein was no longer detectable and we see a substantial reduction in Trio staining, in that there was a complete loss of neurons with α'/β' characteristic gene expression (Abrupt negative cells expressing Trio in both the cytoplasm and plasma membrane; Trio^PM,Cyto^/Abrupt^-^). The slow action of *mamo-*RNAi and the progressive reduction of Trio staining, suggests that with a longer RNAi induction, Trio would disappear completely.

> Similarly, misexpress Mamo in specifically in adults (OK107-Gal4, Gal80.ts, UAS-mamo-GOF) and assay for ectopic a\'/b\' neurons.

This data is also included in Figure 6 and Figure 6---figure supplements 1 and 2 and a new section in the Results (Mamo stimulates α'/β' specific gene expression in mature MB neurons). As predicted, overexpressing Mamo in adult MBs also caused a significant (p\<0.01) shift to produce more neurons with α'/β' characteristic gene expression (Trio^PM,Cyto^/Abrupt-), from 22% in the control to 42% with *mamo-GOF*.

> 2\) Overexpress constitutive Mamo (replace UTRs) and assay for Imp, Syp, and Chinmo. All three should have normal expression patterns if the hierarchical regulation model is true. This is technically trivial, and the mamo construct is even mentioned in the Discussion (although incorrectly cited as being in Figure 4L, which is a different experiment).

We have included in a new supplementary figure (Figure 5---figure supplement 2) to address this point.

The Results section reads:

"...either the *mamo-RF* or *mamo-RG* isoform lies downstream of Imp/Syp gradients and Chinmo in α'/β' temporal fate determination. In further support of a hierarchy, 4ZF Mamo overexpression does not alter Imp, Syp or Chinmo levels (Figure 5---figure supplement 2)."

We have corrected the citation.

> In addition, the following additional points need to be clarified:
>
> I\) They need to quantity the number of neurons present/missing in the different genetic backgrounds. This can be done either using the markers the authors describe in the manuscript, or using cell-type specific Gal4/LexA lines. A general question that arises throughout the manuscript is to address the fate of neurons born in different temporal windows when Chinmo, Mamo, Imp or Syp are missing.

As the neuronal fate markers are not distinguishable during larval stages, it is difficult to assess the neuronal fate until the late pupa or adult stage. Therefore, we have addressed the neuronal fate in adult stages in Figure 5. We include quantifications for all three neuron populations for most genotypes (Figure 5B, D, F and Figure 5---figure supplement 3).

> II\) They also need to clearly indicate in all figures newborn vs. maturing vs. mature neurons. An outline around the different neuron populations (i.e., newborn vs. mature) would make it easier to understand the different expression domains.

Newborn and young/maturing neurons are identified in Figures 1-4. Newborn neurons are identified by the very dim GFP expression as described in Zhu et al., 2006. Young/maturing neurons lie immediately adjacent to the newborn neurons with a slightly higher GFP intensity than newborn neurons.

> III\) Finally, the authors need to quantify fluorescence intensity values for Chinmo and Mamo in control and all mutant backgrounds.

Quantifications are now included in Figure 1---figure supplement 1, Figure 2---figure supplement 1, Figure 3---figure supplement 1, Figure 3---figure supplement 2, and Figure 4---figure supplement 1.

> In more detail:
>
> \- In Figure 1, the authors use OK107-Gal4 to label mushroom body neurons. According to Figure 1A, this driver labels more than 1 neuron type in the mushroom bodies after 72 hrs. Thus, it is not possible to determine whether the Mamo positive staining in 1C is in γ neurons or in α'β' neurons, particularly since maturing vs. newborn neurons is not clearly defined. The authors need to do the same staining using either a γ-Gal4 line (e.g., 201y-Gal4 or 71G10-Gal4) or an α'β'-Gal4 line.

We have now defined the newborn and young/maturing neuronal populations throughout Figure 1. In 1C, Mamo positive cells are confined to the young/maturing neuronal population. A new figure (Figure 1---figure supplement 1B) further addresses that γ neurons (marked by 201y-Gal4) are negative for Mamo at 84h ALH and Figure 1---figure supplement 1C shows the onset of γ neuron expression of Mamo at 0h APF.

The text reads:

"To validate that at 84h ALH, Mamo is in fact expressed in prospective α'/β' rather than γ neurons, we used a γ neuron-specific driver and confirmed that there is no overlap with Mamo expression (Figure 1---figure supplement 1B)."

> \- Similar to the above comment, the authors need to determine which mushroom body cells are Mamo positive in Figure 1D. At this stage, all three mushroom neuron types are present. Do all neuron types eventually become Mamo positive? For example, since Chinmo is not maintained, does Mamo become activated in all cells that once expressed Chinmo once Chinmo levels decline (as shown in Figure 1D)? If so, it would help validate part of the authors model that low Chinmo activates Mamo. The authors need to use Gal4 lines that label the different mushroom body neuron types and stain/quantify Mamo and Chinmo levels during development.

Please see the point above to address some aspects.

In Figure 1D, both γ and α'/β' neurons are Mamo positive. We now show in Figure 1---figure supplement 1C that at 0h APF γ neurons expressed Mamo in addition to a second population (α'/β'). In addition, we have included a new figure (Figure 6---figure supplement 1C) to address Mamo expression in the adult MB. Mamo is expressed in γ and α'/β' neurons (identified by Trio^PM^ and Trio^PM,Cyto^). It is, however, not clear whether the γ neuron induction of Mamo is related to Chinmo levels.

Text in the Results section:

"γ neurons, which express high Chinmo in early larval stages, begin to express Mamo during puparium formation (Figure 1---figure supplement 1C)."

Text in the Discussion:

"Transcription initiation is not the only requirement for Mamo protein expression; Syp is also required (Figures 3 and 4, discussed below). \[...\] It has not yet been tested whether weak Chinmo levels are required for later Mamo expression in γ neurons. It is therefore possible that Mamo expression is controlled at this stage by an additional factor(s)."

> \- Chinmo and Mamo levels should be quantified in newborn/maturing/mature neurons through time in Figure 1B-D.

We have included quantification in a new figure (Figure 1---figure supplement 1A).

> \- Quantify Chinmo levels at 84 ALH in Figure 2. It is not enough to place stars in the cartoon, especially since the authors want to show that low Chinmo activates Mamo. At 48h ALH, in Figure 3---figure supplement 1D, Chinmo levels already look undetectable. This is a major point of the paper that should be better characterized/quantified.

We have included a new quantification result in Figure 3---figure supplement 1G. We agree that the intensity of Chinmo immunostaining is difficult to visualize. Weak Chinmo levels are hard to see, but immunofluorescent quantification helps us understand how modifying genotype can affect Chinmo levels. We see low Chinmo levels in any genetic manipulation expected to cause a Chinmo reduction.

> \- In Figure 2D, the authors need to define what the additional Mamo positive neurons are within the clones. Are they γ neurons (they have low Chinmo, and so they might activate Mamo), or are they additional α'β' neurons specified earlier? The same is true for Figure 2F. Given the context of the manuscript, it is assumed that they are additional α'β' neurons but the authors need to demonstrate this point and state clearly their conclusion.

We wish we could easily address cell fate of Mamo positive cells in *chinmo-*RNAi expressing animals during larval stages (Figures 2D and F). However, due to lack of larval cell-type markers, we instead wait until adult stages when cell fate can be better distinguished (Figure 5D and D'). We have now provided the percentages of adult MB neuron fates based on Trio and Abrupt markers (Figure 5---figure supplement 3).

*Chinmo-RNAi* causes a decrease in the percent of γ neurons, the percent of α'/β' neurons did not change considerably from control animals, but the percent of α/β neurons expanded significantly.

Clearly, the prematurely expressing Mamo cells do not become γ neurons, as γ neurons decreased from \~40% in control animals to \~20% with *chinmo-RNAi*. This is supported by additional findings that γ neurons do not turn on Mamo until they undergo remodeling around puparium formation (Figure 1---figure supplement 1B and C). We believe this is due to lack of Syp expression in γ neurons. We have additional data that will be included in a subsequent paper regarding the cause of this onset of Mamo in γ neurons. (Liu et al., in preparation). However, as of this time, we have not tested whether weak Chinmo is also required for pupal onset of Mamo. We now include discussion of this point (subsection "Weak Chinmo on Mamo protein expression").

Together, this suggests that the weak Chinmo expression window and subsequent Mamo expression window shifted earlier rather than being extended. The Chinmo expression levels with *chinmo-RNAi* were very low (Figure 3---figure supplement 1G, compare 72h ALH control with 48h *chinmo-RNAi*) and any subsequent reduction (by Syp post-transcriptional regulation) would likely result in a Chinmo-off window, and thus α/β neurons.

The Results now state:

"With premature weak Chinmo (*chinmo-RNAi),* g neuron production significantly (p\<0.001) decreased from 38 ± 0.3% in control animals to 18 ± 1.6% with *chinmo-RNAi* (Figure 5D and D' and Figure 5---figure supplement 3). \[...\] The percentage of α/β characteristic Abrubtp^-^/Trio^-^ cells increased from 41 ± 0.5% in control to 64 ± 1.1% with *chinmo-RNAi* [(]{.ul}p\<0.001)."

> \- In Figure 3D, Mamo expression is lost at 84 ALH. However, the authors have previously reported (Lee, Science) that overexpression of Imp or Syp leads to additional α'β' neurons in the adult, while later in this manuscript, they demonstrate that Mamo is necessary for α'β' identity. Thus, the authors should put their new findings in context of their previous results. When are additional α'β' neurons born according to their current model? In the pupal window?

In order to improve flow/understanding and provide a clearer justification of why we examined Syp's role in Mamo expression, we decided to remove Imp data from Figure 3. We felt that it distracted from, rather than clarified our main points.

However, to address your question, in Imp overexpression, Chinmo is still expressed in newborn neurons at pupal stages (a time when Chinmo is normally off). We therefore believe that additional α'/β' neurons are generated in the pupal window.
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> \- For Figure 4, the authors need to quantify the smFISH results. For example, it is difficult to know if there is a difference in mature transcript abundance between 4M and 4H. They must show the smFISH results in a Syp-RNAi background alone (They do show Syp-RNAi with Chinmo RNAi).

We have included quantification for *mamo* mature transcripts in Figure 4---figure supplement 1. As there is no Mamo protein produced with Syp-RNAi, we do not feel that the smFISH experiment is essential. Chinmo-RNAi servers as a control for Chinmo-RNAi with Syp-RNAi.

> \- Figure 5H: Syp-RNAi with Mamo-GOF results in a mushroom body with a majority of α'β' neurons. However, throughout the manuscript, the authors have made a point to indicate that Mamo requires post-transcriptional regulation by Syp. Thus, this result seems to contradict the authors\' earlier results as Mamo-GOF should not lead to additional α'β' neurons in the absence of Syp. This apparent discrepancy must be addressed.

We apologize for any misunderstanding. The *Mamo-GOF* experiments utilize a transgene that does not have UTRs or introns and thus is not subject to Syp post-transcriptional regulation. We have now made this clear in the text when recounting the testing of Mamo transgenes and when describing Figure 5H.

> \- The authors must quantify the number of α'β' neurons in the different genetic backgrounds in Figure 5 (e.g. using strong Trio expression of more than one marker.

We have quantified cell type percentages for Control animals, *chinmo-RNAi* and Mamo overexpression geneotypes in Figure 5---figure supplement 3. *mamo-RNAi, chinmo-RNAi plus mamo-RNAi, and syp-RNAi* all lack α'/β' neurons, shifting to nearly all α/β or γ neurons so quantifications were not crucial to understand how cell fate was altered.
